U.S. Hotel and Resort REITs Stock News

Amicus Therapeutics (FOLD) has been drawing attention after a strong past 3 months, with a total return of 32.1% and 61.5% over the past year, prompting fresh questions about what is driving sentiment. See our latest analysis for Amicus Therapeutics. The current share price of $14.37 comes after a relatively quiet few weeks in terms of short term share price movement. However, the 90 day share price return of 32.08% alongside a 1 year total shareholder return of 61.46% suggests that momentum...

Illumina (ILMN) is back in focus after the company and Nashville Biosciences expanded the Alliance for Genomic Discovery to 312,000 whole genomes and launched a 50,000 sample genome proteomics pairing initiative. See our latest analysis for Illumina. Illumina’s recent Alliance for Genomic Discovery expansion and multiomic push come as the share price sits at US$118.94, with a 1-day share price return of 2.92% but a year to date share price return decline of 11.47%. The 1-year total...

VEON Ltd. has reported past fourth-quarter 2025 revenue of US$1,171 million, up from US$998 million a year earlier, but swung to a net loss of US$31 million for the quarter even as full-year 2025 net income increased to US$532 million on higher sales of US$4,399 million. Alongside this, VEON set out 2026 guidance targeting total revenue growth of 9%–12% in US$ terms and expanded its digital and AI partnerships across key markets, including Uzbekistan, Pakistan, Bangladesh, and broader...

If you are trying to figure out whether StoneCo at around US$13.81 is a bargain or a trap, you are in the right place to focus on what the current price really reflects. The stock has had a mixed ride, with a 0.7% return over the last 7 days, an 18.1% decline over 30 days, a 6.0% decline year to date, a 42.1% return over 1 year and 55.7% over 3 years, while still sitting 79.4% below its 5-year level. Recent headlines around StoneCo have largely centered on its role in Brazil's payments and...

T1 Energy (TE) has been in focus after investor optimism picked up ahead of its upcoming fourth quarter and full year 2025 earnings release, along with fresh support from Section 45X tax credit eligibility. See our latest analysis for T1 Energy. The recent rally, including a 13.39% 7 day share price return and 50.59% 90 day share price return to US$7.62, has coincided with Section 45X tax credit support and earnings anticipation. At the same time, the year to date share price return shows a...

MSCI (MSCI) is back in focus after Snowden Lane Partners said it will integrate the MSCI Wealth Manager platform into its advisory ecosystem, putting the company’s portfolio analytics and tax aware tools in front of more advisors. See our latest analysis for MSCI. MSCI’s shares trade at US$547.90, with a 30 day share price return of 4.15% after a softer 7 day share price return of 3.75%, while the 1 year total shareholder return of 0.10% and 5 year total shareholder return of 40.84% point to...

Multiple class action lawsuits have been filed against monday.com in the past week. Complaints focus on alleged misstatements about revenue growth momentum and expansion outlook. Investor groups claim recent guidance and business shifts exposed earlier disclosures as misleading. The cases target monday.com ordinary shares traded on NasdaqGS:MNDY. monday.com, which trades on NasdaqGS:MNDY, is now dealing with legal pressure alongside a challenging share price history. The stock closed at...

Earlier this month, CareTrust REIT, Inc. increased its quarterly common stock cash dividend from US$0.335 to US$0.39 per share, payable to stockholders of record as of March 31, 2026, with payment intended around April 15, 2026. This higher dividend highlights management’s emphasis on returning more cash to shareholders, a key consideration for income-focused real estate investors assessing the REIT’s appeal. We’ll now examine how this higher quarterly dividend payout fits into CareTrust...

WeRide (NasdaqGM:WRD) shareholders approved a comprehensive governance overhaul at an extraordinary general meeting. The company adopted a fully updated memorandum and articles of association and refreshed its equity and share mandate framework. A new 2026 Share Plan was also approved, setting fresh parameters for future equity-based incentives. WeRide, listed as NasdaqGM:WRD, operates in autonomous driving and related mobility solutions. In this sector, access to capital and board...

In recent days, AdaptHealth Corp. disclosed that major shareholder Richard M. Cashin Jr. purchased about 2,046,691 additional shares of the company’s common stock, lifting his reporting group’s stake to 15,864,871 shares in a transaction worth nearly US$20,000,000. This sizeable insider purchase by a 10% owner comes shortly after AdaptHealth reported a quarterly earnings per share of US$0.76, which fell well short of expectations even as revenue slightly exceeded forecasts, drawing attention...

If you are wondering whether DENTSPLY SIRONA is attractively priced at its current level, this article walks through what the numbers say about the stock’s value. The share price last closed at US$11.54, with returns of a 9.4% decline over 7 days, a 10.9% decline over 30 days, a 2.4% gain year to date, and a 22.2% decline over 1 year. The 3 year and 5 year returns stand at a 65.8% decline and a 79.5% decline respectively. These moves have kept DENTSPLY SIRONA in focus for investors watching...

What Syndax Pharmaceuticals (SNDX) Investors Are Watching Right Now Syndax Pharmaceuticals (SNDX) has drawn fresh attention after recent trading, with the stock closing at US$23.50 and showing double digit total returns over the past year and the past 3 months. See our latest analysis for Syndax Pharmaceuticals. That latest 1 day share price decline of 2.04% comes after a strong run, with a 30 day share price return of 14.75% and 1 year total shareholder return of 81.47%. This suggests...

In recent weeks, TransMedics Group reported fourth-quarter results that exceeded analyst expectations and updated investors with what analysts described as a strong 2026 outlook. Analysts highlighted the company’s continued investment in heart and lung transplant technology and its intention to expand into kidney, underscoring confidence in its clinical platform. Building on this upbeat outlook and kidney expansion focus, we’ll now explore how the latest developments may reshape TransMedics’...

Earlier this month, Payoneer Global Inc. announced a collaboration with FundPark to offer AI-driven digital financing solutions and flexible credit lines of up to US$10 million for eligible Hong Kong–incorporated e-commerce businesses using Payoneer’s cross-border, multi-currency platform. This partnership directly targets financing gaps for asset-light, cross-border merchants, potentially deepening Payoneer’s role in supporting small and mid-sized exporters’ working capital needs and global...

If you are wondering whether Columbia Sportswear is attractively priced or just a value trap, this article walks through what the numbers actually say about the stock. With the share price at US$55.25 and returns of a 5.3% decline over 7 days, 12.7% decline over 30 days, 1.4% decline year to date, 28.0% decline over 1 year and 32.4% decline over 3 years, the market has clearly reset expectations over time. Recent coverage has focused on Columbia Sportswear as a long established outdoor...

If you are wondering whether DexCom's current share price reflects its long term potential, this breakdown will help you separate story from sticker price. At a last close of US$64.24, DexCom's shareholders have seen 7 day and 30 day returns of 5.7% and 8.3% declines, with the 1 year return at a 9.1% decline and the 3 and 5 year returns at 43.6% and 25.4% declines. Recent coverage of DexCom has focused on its position in continuous glucose monitoring and how the stock's pullback has affected...

Tetra Tech (TTEK) is back on investor radars after securing a US$99 million, five year architect engineer contract with NAVFAC Southeast, alongside earnings that exceeded analyst expectations and two acquisitions focused on defense consulting. See our latest analysis for Tetra Tech. Despite winning new defense focused work and reporting results ahead of expectations, the recent tone in the market has been cautious. The 30 day share price return shows a decline of 12.3% and the 7 day share...

Why Watts Water Technologies Stock Is on Investors’ Radars Watts Water Technologies (WTS) has drawn attention after recent share price moves, including a 1-day decline of 1.8% and a month return of 9.4% in negative territory. Investors are reassessing the plumbing and HVAC solutions supplier’s current valuation. See our latest analysis for Watts Water Technologies. At a share price of US$297.8, Watts Water Technologies has pulled back with a 1-month share price return of 9.35% in the red...

Box (BOX) is back in focus after releasing fourth quarter and full year results, updating investors on sales, earnings and fresh guidance that spells out expected revenue growth and foreign exchange impacts. See our latest analysis for Box. Box shares trade at US$24.89 after a recent 30 day share price return of 7.33%, although the year to date share price return of 13.67% and 1 year total shareholder return of 20.33% show momentum has been fading despite the latest earnings, guidance and...

Why Science Applications International Is On Investors’ Radar Science Applications International (SAIC) has been drawing attention after recent share price moves, including a month gain of about 6% and a past 3 months decline of roughly 10%. This has prompted investors to reassess its current valuation. See our latest analysis for Science Applications International. That recent 6.1% 30 day share price return contrasts with a 9.2% year to date share price decline and a 10.8% one year total...

Evolv Technologies Holdings (EVLV) is back in focus after a busy March, with Q4 results topping revenue expectations, 2026 guidance moving higher, and fresh multi year renewals with major stadium clients. See our latest analysis for Evolv Technologies Holdings. The recent contract wins and raised 2026 guidance come after a tougher start to the year for the share price, with a 30 day share price return of 10.04% and a 90 day share price return of 24.41%. Yet longer term total shareholder...

Earlier in March 2026, Relay Therapeutics amended and restated its bylaws to require U.S. federal district courts as the exclusive forum for securities law claims, while its CFO, Thomas Catinazzo, reported additional share sales. At the same time, investor focus has intensified on Relay’s zovegalisib phase III program in advanced breast cancer, alongside higher consensus EPS estimates for the upcoming quarter. We’ll now explore how the heightened optimism around zovegalisib’s phase III...

BWS Financial recently highlighted A10 Networks’ record fourth-quarter revenue and management’s expectation for 2026 revenue growth of 10% to 12%, attributing momentum to rising AI-related network traffic and demand for high-throughput networking and security solutions. The research underscored that A10’s security and infrastructure products are increasingly embedded in AI-focused data center and enterprise network buildouts, suggesting AI workloads are becoming a more central driver of...

In early March 2026, John Wiley & Sons reported improved third-quarter profitability and completed two share repurchase tranches totaling 1,094,535 shares for US$35.03 million, while OpenEvidence announced a partnership to integrate Wiley’s extensive medical and scientific content into its physician-facing clinical decision platform. Beyond the headline numbers, the combination of higher earnings, ongoing buybacks, and deeper integration into AI-powered clinical workflows highlights how...